Cost-Effectiveness of the 21-Gene Breast Cancer Assay in Mexico-Reference-Cited by-同舟云学术

Cost-Effectiveness of the 21-Gene Breast Cancer Assay in Mexico

Published:2015-03 Issue:3 Volume:32 Page:239-253
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Bargalló-Rocha Juan Enrique,Lara-Medina Fernando,Pérez-Sánchez Victor,Vázquez-Romo Rafael,Villarreal-Garza Cynthia,Martínez-Said Hector,Shaw-Dulin Robin J.,Mohar-Betancourt Alejandro,Hunt Barnaby,Plun-Favreau Juliette,Valentine William J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12325-015-0190-8.pdf

Reference38 articles.

1. Porter P. “Westernizing” women’s risks? Breast cancer in lower-income countries. N Engl J Med. 2008;358(3):213–6.

2. Rodríguez-Cuevas S, Macías C, Labastida S. Cáncer de mama en México: ¿enfermedad de mujeres jóvenes? Ginecol Obstet Mex. 2000;68(5):185–90.

3. Knaul FM, Nigenda G, Lozano R, Arreola-Ornelas H, Langer A, Frenk J. Breast cancer in Mexico: a pressing priority. Reprod Health Matters. 2008;16(32):113–23.

4. Knaul FM, Arreola-Ornelas H, Velázquez E, Dorantes J, Méndez O, Avila-Burgos L. The health care costs of breast cancer: the case of the Mexican Social Security Institute. Salud Publica Mex. 2009;51(Suppl 2):s286–95.

5. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–34.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Correlation of Magee Equations and Oncotype Dx Recurrence Score in Mexican Patients Diagnosed with Early Breast Cancer;2024

2. Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis;Frontiers in Oncology;2023-06-23

3. Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study;Therapeutic Advances in Medical Oncology;2022-01

4. Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach;Human Pathology Reports;2021-11

5. Practice-Changing Use of the 21-Gene Test for the Management of Patients With Early-Stage Breast Cancer in Latin America;JCO Global Oncology;2021-08